• Explore /
  • Poster
  • / Outcomes for patients in the pembrolizumab+axitinib arm with advanced renal cell carcinoma (RCC) who completed two years of treatment in the phase III KEYNOTE-426 study.

Outcomes for patients in the pembrolizumab+axitinib arm with advanced renal cell carcinoma (RCC) who completed two years of treatment in the phase III KEYNOTE-426 study.

Abstract Poster

Authors

Elizabeth Plimack

Elizabeth R. Plimack

Fox Chase Cancer Center, Philadelphia, PA

Elizabeth R. Plimack , Thomas Powles , Jens Bedke , Frédéric Pouliot , Viktor Stus , Tom Waddell , Rustem Gafanov , Dmitry Nosov , Boris Alekseev , Raymond S. McDermott , Maurice Markus , Sophie Tartas , Anna Kryzhanivska , Igor Bondarenko , Cezary Szczylik , Jianxin Lin , Rodolfo F. Perini , L. Rhoda Molife , Michael B. Atkins , Brian I. Rini

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session: Renal Cell Cancer

Track

Renal Cell Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT02853331

Citation

J Clin Oncol 39, 2021 (suppl 6; abstr 327)

DOI

10.1200/JCO.2021.39.6_suppl.327

Abstract #

327

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Bradley Alexander McGregor

First Author: Carissa Beaulieu

First Author: Ulka N. Vaishampayan

First Author: Michael B. Atkins